Raphas Co. Ltd (KQ:214260) — Market Cap & Net Worth
Market Cap & Net Worth: Raphas Co. Ltd (214260)
Raphas Co. Ltd (KQ:214260) has a market capitalization of $54.13 Million (₩79.88 Billion) as of May 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21593 globally and #1397 in its home market, demonstrating a -1.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Raphas Co. Ltd's stock price ₩9500.00 by its total outstanding shares 8408463 (8.41 Million). Analyse Raphas Co. Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Raphas Co. Ltd Market Cap History: 2020 to 2026
Raphas Co. Ltd's market capitalization history from 2020 to 2026. Data shows change from $138.18 Million to $54.13 Million (-15.05% CAGR).
Index Memberships
Raphas Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.02% | #682 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.02% | #682 of 1384 |
Weight: Raphas Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Raphas Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Raphas Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Raphas Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $138.18 Million | $17.86 Billion | -$4.54 Billion | 0.01x | N/A |
| 2021 | $253.86 Million | $20.34 Billion | $4.93 Billion | 0.01x | 0.05x |
| 2022 | $90.60 Million | $23.64 Billion | -$8.51 Billion | 0.00x | N/A |
| 2023 | $109.92 Million | $27.94 Billion | -$8.80 Billion | 0.00x | N/A |
| 2024 | $84.73 Million | $27.22 Billion | -$4.77 Billion | 0.00x | N/A |
Competitor Companies of 214260 by Market Capitalization
Companies near Raphas Co. Ltd in the global market cap rankings as of May 5, 2026.
Key companies related to Raphas Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Raphas Co. Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Raphas Co. Ltd's market cap moved from $138.18 Million to $ 54.13 Million, with a yearly change of -15.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩54.13 Million | -27.48% |
| 2025 | ₩74.65 Million | -11.90% |
| 2024 | ₩84.73 Million | -22.91% |
| 2023 | ₩109.92 Million | +21.32% |
| 2022 | ₩90.60 Million | -64.31% |
| 2021 | ₩253.86 Million | +83.71% |
| 2020 | ₩138.18 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Raphas Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.13 Million USD |
| MoneyControl | $54.13 Million USD |
| MarketWatch | $54.13 Million USD |
| marketcap.company | $54.13 Million USD |
| Reuters | $54.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more